Diagnosis and Treatment of Multiple Sclerosis: Guidelines - CADTH RAPID RESPONSE REPORT: REFERENCE LIST
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
CADTH RAPID RESPONSE REPORT: REFERENCE LIST Diagnosis and Treatment of Multiple Sclerosis: Guidelines Service Line: Rapid Response Service Version: 1.0 Publication Date: January 3, 2018 Report Length: 6 Pages
Authors: Kelsey Seal, Lorna Adcock
Cite As: Diagnosis and treatment of multiple sclerosis: guidelines . Ottawa: CADTH; 2018 Jan. (CADTH rapid response report: ref erence list).
Acknowledgments:
Disclaimer: The inf ormation in this document is intended to help Canadian health care decision-makers, health care prof essionals, health sy stems leaders,
and policy -makers make well-inf ormed decisions and thereby improv e the quality of health care serv ices. While patients and others may access this documen t,
the document is made av ailable f or inf ormational purposes only and no representations or warranties are made with respect to its f itness f or any particular
purpose. The inf ormation in this document should not be used as a substitute f or prof essional medical adv ice or as a substitu te f or the application of clinical
judgment in respect of the care of a particular patient or other prof essional judgment in any decision-making process. The Canadian Agency f or Drugs and
Technologies in Health (CADTH) does not endorse any inf ormation, drugs, therapies, treatments, products, processes, or serv ices.
While care has been taken to ensure that the inf ormation prepared by CADTH in this document is accurate, complete, and up -to-date as at the applicable date
the material was f irst published by CADTH, CADTH does not make any guarantees to that ef f ect. CADTH does not guarantee and is not responsible f or the
quality , currency , propriety , accuracy, or reasonableness of any statements, information, or conclusions contained in any thi rd-party materials used in preparing
this document. The v iews and opinions of third parties published in this document do not necessarily state or ref lect those of CADTH.
CADTH is not responsible f or any errors, omissions, injury , loss, or damage arising f rom or relating to the use (or misuse) o f any inf ormation, statements, or
conclusions contained in or implied by the contents of this document or any of the source materials.
This document may contain links to third-party websites. CADTH does not hav e control ov er the content of such sites. Use of third-party sites is gov erned by
the third-party website owners’ own terms and conditions set out f or such sites. CADTH does not make any guarantee with respect to any inf ormation
contained on such third-party sites and CADTH is not responsible f or any injury , loss, or damage suf f ered as a result of using such third-party sites. CADTH
has no responsibility f or the collection, use, and disclosure of personal inf ormation by third-party sites.
Subject to the af orementioned limitations, the v iews expressed herein are those of CADTH and do not necessarily represent the v iews of Canada’s f ederal,
prov incial, or territorial gov ernments or any third party supplier of inf ormation.
This document is prepared and intended f or use in the context of the Canadian health care sy stem. The use of this document outside of Canada is done so at
the user’s own risk.
This disclaimer and any questions or matters of any nature arising f rom or relating to the content or use (or misuse) of this document will be gov erned by and
interpreted in accordance with the laws of the Prov ince of Ontario and the laws of Canada applicable therein, and all proceedings shall b e subject to the
exclusiv e jurisdiction of the courts of the Prov ince of Ontario, Canada.
The copy right and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian
Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document f or non -commercial purposes
only , prov ided it is not modif ied when reproduced and appropriate credit is giv en to CADTH and its licensors.
About CADTH: CADTH is an independent, not-f or-prof it organization responsible f or prov iding Canada’s health care decision-makers with objectiv e ev idence
to help make inf ormed decisions about the optimal use of drugs, medical dev ices, diagnostics, and procedures in our health ca re sy stem.
Funding: CADTH receiv es f unding f rom Canada’s f ederal, prov incial, and territorial gov ernments, with the exception of Quebec.
REFERENCE LIST Diagnosis and Treatment of Multiple Sclerosis 2Research Question
What are the evidence-based guidelines for the full spectrum of care (including diagnosis
and treatment) of patients with multiple sclerosis?
Key Findings
One evidence-based guideline was identified regarding the full spectrum of care (including
diagnosis and treatment) of patients with multiple sclerosis.
Methods
A limited literature search was conducted on key resources including PubMed, The
Cochrane Library, University of York Centre for Reviews and Dissemination (CRD)
databases and a focused Internet search. Methodological filters were applied to limit
retrieval to guidelines. The search was limited to English language documents published
between January 1, 2012 and December 19, 2017. Internet links were provided, where
available.
Selection Criteria
One reviewer screened citations and selected studies based on the inclusion criteria
presented in Table 1.
Table 1: Selection Criteria
Population Adults (> 18 years) patients with multiple sclerosis
Intervention Diagnostic methods (including screening, diagnostic tools, and devices);
Treatment methods (including pharmacological and non-pharmacological treatment)
Comparator No comparator
Outcomes Guidelines
Study Designs Evidence-based guidelines
Results
One evidence-based guideline was identified regarding the full spectrum of care (including
diagnosis and treatment) of patients with multiple sclerosis.
REFERENCE LIST Diagnosis and Treatment of Multiple Sclerosis 3Additional references of potential interest are provided in the appendix.
Guidelines and Recommendations
1. Multiple sclerosis in adults: management [Internet]. London: National Institute for Health
and Care Excellence; 2014. [cited 2018 Jan 3]. (NICE guideline; no. 186). Available
from: https://www.nice.org.uk/guidance/cg186
REFERENCE LIST Diagnosis and Treatment of Multiple Sclerosis 4Appendix — Further Information
Previous CADTH Reports
2. Treatment of patients with multiple sclerosis: a review of guidelines [Internet]. Ottawa:
CADTH; 2013 Mar 13. [cited 2018 Jan 3]. (CADTH Rapid response report: s ummary
with critical appraisal). Available from: https://www.cadth.ca/treatment-patients-
multiple-sclerosis-review-guidelines-0
3. Care of patients with m ultiple sclerosis: guidelines [Internet]. Ottawa: CADTH; 2012
Feb10 [cited 2018 Jan 3]. (CADTH Rapid response report: reference list). Available
from: https://www.cadth.ca/care-patients-multiple-sclerosis-guidelines
4. Management of relapsing-remitting multiple sclerosis [Internet]. Ottawa: CADTH; 2012
Nov 29. [cited 2018 Jan 3]. (CADTH Therapeutic review; vol. 1 no. 2a). Available from:
https://www.cadth.ca/management-relapsing-remitting-multiple-sclerosis
Systematic Reviews
5. Comini-Frota ER, Vasconcelos CC, Mendes MF. Guideline for multiple sclerosis
treatment in Brazil: consensus from the Neuroimmunology Scientific Department of the
Brazilian Academy of Neurology. Arq Neuropsiquiatr. 2017 Jan;75(1):57-65.
PubMed: PM28099564
Randomized Controlled Trials
6. Coote S, Uszynski M, Herring MP, Hayes S, Scarrott C, Newell J, et al. Effect of
exercising at minimum recommendations of the multiple sclerosis exercise guideline
combined with structured education or attention control education - secondary results of
the step it up randomised controlled trial. BMC Neurol [Internet]. 2017 Jun 24 [cited
2018 Jan 3];17(1):119. Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483256
PubMed:PM28646860
Non-Randomized Studies
7. Gajofatto A, Nourbakhsh B, Benedetti MD, Waubant E. Performance of 2010 McDonald
criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple
sclerosis. J Neurol Neurosurg Psychiatry. 2017 Sep 22.
PubMed:PM28939685
Guidelines – Uncertain Methodology
8. Luzzio C, Dangond, F. Multiple sclerosis guidelines. In: Medscape [Internet]. New York:
Medscape LLC; 2017 [cited 2018 Jan 3]. Available from:
https://emedicine.medscape.com/article/1146199-guidelines
9. Identification and management of depression in multiple sclerosis: clinical practice
guideline [Internet]. Edmonton (AB): Towards Optimized Practice; 2015. [cited 2018 Jan
3]. Available from:
https://www.topalbertadoctors.org/download/1898/Depression%20in%20MS%20CPG.p
df?_20170928205308
10. Traboulsee A, Letourneau-Guillon L, Freedman MS, O'Connor PW, Bharatha A,
Chakraborty S, et al. Canadian Expert Panel recommendations for MRI Use in MS
REFERENCE LIST Diagnosis and Treatment of Multiple Sclerosis 5diagnosis and m onitoring. Can J Neurol Sci [Internet]. 2015 May [cited 2018 Jan
3];42(3):159-67. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416356
PubMed: PM25896163
11. Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, et al. Treatment
optimization in MS: Canadian MS Working Group updated recommendations. Can J
Neurol Sci. 2013 May;40(3):307-23.
PubMed:PM23603165
Additional References
12. Kes VB, Zavoreo I, Seric V, Solter VV, Cesarik M, Hajnsek S, et al. Recommendations
for diagnosis and management of multiple sclerosis. Acta Clin Croat. 2012
Mar;51(1):117-35.
PubMed:PM22920014
REFERENCE LIST Diagnosis and Treatment of Multiple Sclerosis 6You can also read
